RemeGen Co (HKSE:09995) Debt-to-Equity : 0.37 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is RemeGen Co Debt-to-Equity?

RemeGen Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$377.0 Mil. RemeGen Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was HK$1,001.1 Mil. RemeGen Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was HK$3,759.6 Mil. RemeGen Co's debt to equity for the quarter that ended in Dec. 2023 was 0.37.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for RemeGen Co's Debt-to-Equity or its related term are showing as below:

HKSE:09995' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.28 Med: 0.03 Max: 0.37
Current: 0.37

During the past 6 years, the highest Debt-to-Equity Ratio of RemeGen Co was 0.37. The lowest was -0.28. And the median was 0.03.

HKSE:09995's Debt-to-Equity is ranked worse than
69.3% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs HKSE:09995: 0.37

RemeGen Co Debt-to-Equity Historical Data

The historical data trend for RemeGen Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RemeGen Co Debt-to-Equity Chart

RemeGen Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.28

0.06

0.03

0.37

RemeGen Co Quarterly Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial									0.03	0.16	N/A	0.37	N/A

Competitive Comparison of RemeGen Co's Debt-to-Equity

For the Biotechnology subindustry, RemeGen Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RemeGen Co's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RemeGen Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where RemeGen Co's Debt-to-Equity falls into.

RemeGen Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

RemeGen Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(377.047	+	1001.095)	/	3759.612
	=	0.37

RemeGen Co's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(377.047	+	1001.095)	/	3759.612
	=	0.37

RemeGen Co (HKSE:09995) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

RemeGen Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of RemeGen Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

RemeGen Co (HKSE:09995) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » RemeGen Co Ltd (HKSE:09995) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

REGMF:USA REG:Germany 688331:China

Address

58 Middle Beijing Road, Yantai Area of Shandong Pilot Free Trade Zone, Yantai Development Zone, Yantai, CHN

Website

http://www.remegen.com

RemeGen was established in 2008 and listed on the Hong Kong Stock Exchange in 2020. It is a commercial stage biotech company focused on developing drugs to treat autoimmune disease, cancer, and ophthalmic disease for the China market and potentially the global market, as well. Its core assets are disitamab vedotin (RC48), a HER2-targeting antibody-drug conjugate (ADC) for treating HER2-expressing cancers, and telitacicept (RC18), a BLyS and APRIL targeting bispecific fusion protein for treating various B-cell mediated autoimmune diseases. These drugs received their first approvals in China in 2021 and are both covered on the National Reimbursement Drug List (NRDL).

RemeGen Co (HKSE:09995) Headlines

No Headlines